SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)
PFE 25.71+1.9%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: B.REVERE who wrote (259)6/9/1998 7:35:00 PM
From: Anthony Wong  Read Replies (1) of 1722
 
Arterial Vascular CEO Says Firm Is Feeling Acquisitive
June 09, 1998 2:51 PM


MINNEAPOLIS -(Dow Jones)- Arterial Vascular
Engineering Inc. President and Chief Executive Officer
Scott Solano Tuesday said the company is exploring
some 10 to 12 acquisition possibilities, but declined to
comment on recent speculation the company is a leading
contender to buy Pfizer Inc.'s Schneider Worldwide
unit.

Market talk during the past few days pegs Boston
Scientific Corp. (BSX) as a likely buyer of Pfizer's
(PFE) cardiovascular-device subsidiary for $2 billion to
$2.2 billion. Arterial Vascular (AVEI) is considered a
runner-up.

Boston Scientific Chief Financial Officer Larry Best
declined to comment on speculation that Boston
Scientific is a leading contender to acquire Schneider
Worldwide. However, Best said Boston Scientific has
looked into buying Schneider.

"Obviously Schneider is a property everyone has looked
at," he said. "We have looked at it. It has some value to
everyone. It's a matter of how much value."

Best said Boston Scientific continues to be acquisitive
and said investors can expect a small acquisition to be
announced soon. He didn't elaborate.

"It's not large but significant enough to disclose coming
up," Best said.

Speaking at the Piper Jaffray investor conference here
Tuesday, Best said U.S. Food and Drug Administration
approval for its Nir stent is expected in the first two
weeks of July, instead of this month.

Best also said that federal approval for its Radius stent in
the U.S. is imminent, and hopes for approval in the next
several weeks.

Solano said the 10 to 12 acquisition possibilities
considered by Arterial Vascular range from small
purchases to "fairly large" ones and are in various stages
of talks, including some that are just on the radar screen.

Solano said the company has two components to its
pricing strategy in an acquisition. He said the acquisition
would have to fit strategically with the company's
product line. He also said the company looks for deals
that are accretive to earnings and said it isn't "shopping
for dilutive" deals.

If an acquisition is dilutive in the short term, it would
have to be "extremely strategic," he said.

"At some point at the upper end (of purchase prices),
they become dilutive and they have to have a very
dramatic strategic impact in order for us to assume it's
okay for us to move forward with those," Solano said. "I
would prefer not to be very specific regarding the exact
levels of what we're looking at."

The company could face significant earnings dilution if it
completes a deal priced at more than $1.5 billion,
according to observers.

Schneider's primary appeal to Boston Scientific lies in its
strong patent portfolio in nylon angioplasty balloons and
"rapid-exchange" catheters.

Rapid-exchange, or single-operator-exchange, catheters
make switching angioplasty balloons easier than
traditional over-the-wire catheters. In a stent procedure,
doctors must first remove the balloon that performed the
angioplasty before they can go back in with another
balloon to position the stent. They will also occasionally
switch a balloon during an angioplasty if a different size
is needed.

Copyright (c) 1998 Dow Jones & Company, Inc.

All Rights Reserved.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext